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Abstract
BACKGROUND: In patients with brain atrophy, it is not easy to distinguish pathologic uptake of flutemetamol (FMM) in the gray 
matter from nonspecific, physiologic uptake in the white matter. In this paper we suggest an easy image processing method.
MATERIAL AND METHODS: The proof-of-concept study involved three patients with mild cognitive impairment and different 
graphical findings at FMM-PET. Two-phase FMM-PET was acquired; the early phase represented the perfusion of gray matter, 
while the late phase depicted the white matter and beta-amyloid load in the gray matter. The border of the gray matter was 
easily extracted from the early-phase images using thresholding and the isocontour “Edges” color table. The late phase was 
registered with the edge images of the early phase and displayed using alpha-blending.
RESULTS: Early- and late-phase image fusion displayed with appropriate color tables is presented in three different cases to 
illustrate the added value of the suggested approach.
CONCLUSIONS: Composite late-phase images with enhanced gray matter borders strongly facilitate assessment of beta-amyloid 
presence in the gray matter. This is especially helpful in patients with brain atrophy.
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Background
Specialized training is required for evaluating beta-amyloid PET 
brain scans due to the difficulty in distinguishing specific, pathologic 
uptake of 18F-based beta-amyloid seeking tracers (flutemetamol, 
florbetaben, florbetapir) in the gray matter from nonspecific, physi-
ologic uptake in the white matter. This is especially difficult in the 
presence of brain atrophy, when the gray matter ribbon is thin and 
the sulci are flat. Some authors have reported the possibility of using 
Pittsburgh compound B [1] and florbetapir [2, 3] for the assessment 
of brain perfusion; images are acquired several minutes after the 
administration of the radiotracer, when the signal from the brain 
mainly represents the perfusion of gray matter. We endeavored to 
utilize early-phase signal for the delineation of gray matter, and to 
then superimpose its borders on the late-phase image to facilitate 
the determination of uptake in the gray matter, which is related to 
beta-amyloid load. In this paper we suggest an image processing 
method, which is easy to implement and use.
Material and methods
The proof-of-concept study involved three patients with 
mild cognitive impairment and different graphical findings at 
FMM-PET. Patients provided signed, informed consent in the 
course of routine investigation according to the local standard of 
care. Approval from the institutional review board or ethics com-
mittee was not needed for the present work as images were 
processed retrospectively and anonymously, without any impact 
on further patient management. 
Non-contrast, low-dose CT was performed for the purpose of 
attenuation correction. A list mode PET acquisition in the PET/CT 
scanner (Siemens Biograph 40 TrueV HD) followed at the moment 
185 MBq of FMM (Vizamyl, GE HealthCare) was administered. 
Data were acquired for 8 minutes and rebinned to 4 × 2-minute 
datasets for the purpose of motion check only. The motion-free 
interval was chosen and early phase images were iteratively 
reconstructed into a 168 × 168 matrix, 3 iterations, 21 subsets, 
zoom 2, Gaussian filter 2 mm using attenuation, scatter and PSF 
correction. After an uptake time of 90 minutes, late-phase data 
were acquired for 20 minutes and rebinned to 4 × 5 minutes, other 
parameters as stated previously.
Both reconstructed volumes were mutually registered and ori-
ented in the Siemens Multi-Modality Work Place using the 3-D tool. 
Early-phase images were presented in the “Edges” isocontour 
color table and the threshold was set to delineate a thin superficial 
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brain ribbon that mainly represents gray matter. Late-phase 
images were presented in the “spectrum” color table and the 
upper threshold was adjusted to 90% in the pons and cerebel-
lar peduncles. Alpha blending of early-phase edge images with 
late-phase images was done by manually adjusted the mixing 
ratio. Beta-amyloid specific uptake in the gray matter was evalu-
ated in critical areas of the frontal and lateral temporal lobes, 
anterior and posterior cingulum, precuneus and temporo-parietal 
areas including the insula. 
Results
Visualization of the border between white and gray matter 
facilitated the assessment of gray matter uptake, enabling the 
easy distinction between normal, nonspecific FMM uptake in the 
white matter from pathological uptake in the gray matter, consist-
ent with the presence of beta amyloid. This is illustrated by three 
different cases:
 — in Figure 1, a patient with low pretest dementia probability and 
normal FMM-PET is presented;
 — in Figure 2, a patient with high pretest Alzheimer disease pro- 
bability and beta-amyloid positivity at FMM-PET is shown;
 — the added value of our approach is clearly apparent in a more 
complicated case of brain hydrocephalus with atrophy, where 
the gray matter is thin and sulci are flat (Fig. 3). 
Discussion
PET investigation of beta-amyloid performed with an early-phase 
acquisition may become popular as it represents a “one-stop” 
complex PET examination of the brain in dementia [4]. The avail-
able signal from early-phase FMM-PET can easily be employed 
in the delineation of the gray matter to help in the assessment of 
beta-amyloid uptake. We assume similar applicability with other 
beta-amyloid seeking tracers. The crucial advantage of this ap-
proach is the same spatial resolution of both early and late data-
Figure 1. FMM-PET in a 53-year old male with a low pretest probability of dementia. Early-phase image presented in “Hot Body” (A) and “Edges” 
(B) color tables. There is a normal distribution of FMM in the late phase (D); overlay of images (B) and (D) facilitated the assessment of no 
pathologic uptake in the gray matter (C). This finding is not consistent with the presence of beta-amyloid
Figure 2. FMM-PET in a 62-year old female with a high pretest probability of Alzheimer disease. Early-phase image presented in “Hot Body” (A) 
and “Edges” (B) color tables. There is clearly an abnormal distribution of FMM (D) in the late phase; overlay of images (B) and (D) facilitated the 
assessment of increased uptake in the gray matter (C). This finding is consistent with the presence of beta-amyloid
Figure 3. FMM-PET in a 70-year old male with hydrocephalus, brain atrophy and dementia. Early-phase image presented in “Hot Body” (A) and 
“Edges” (B) color tables. The evaluation of the late phase (D) should be done with respect to the thin gray matter ribbon that makes decision 
indeterminate, especially in the frontal lobes. Overlay of images (B) and (D) facilitated the demarcation of gray matter and the assessment of no 
pathologic uptake in the gray matter (C). This finding is not consistent with the presence of beta-amyloid
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sets including the same photon spillover from gray to white and 
white to gray matter; proper thresholding of both studies adequately 
compensates for spillover and thus facilitates the assessment. 
We propose a simple method with the potential to increase 
confidence in reporting FMM-PET. Validation of improved FMM-PET 
diagnostic accuracy should be performed once a larger number of 
early- and late-phase PET datasets with subsequent histological 
beta-amyloid confirmation become available. 
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